Amphotericin B, Lyophilized product (intercalated into a liposomal membrane)

1. Invasive fungal infections after bone barrow transplantation complicated with renal toxicity.2. Patients with renal impairment who contract infections of Aspergillus, Candida, or Cryptococcus species.
3. Treatment for cryptococcus meningitis in HIV-infected patients.
4. Treating infections of Aspergillus, Candida or Cryptococcus, or patients who are not suitable for Amphotericin B deoxycholate treatment, or patients with renal impairment, or patients who cannot tolerate Amphotericin B deoxycholate toxicity.
5. Treating visceral leishmaniasis. For immunocompromised patients who receive Amphotericin B Liposome for Injection as treatment for visceral leishmaniasis, the recurrence rate is high after primary parasite eradication.
6. Empirical treatment for febrile patients with severe neutropenia who are suspected to have fungal infection.